Theraclion S.A.
ALTHE.PA · PAR
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.05 | 0.09 | -0.86 | 0.24 |
| FCF Yield | -19.75% | -14.64% | -21.04% | -13.52% |
| EV / EBITDA | -1.78 | -2.65 | -4.63 | -6.76 |
| Quality | ||||
| ROIC | -76.99% | -20.55% | -45.02% | -44.48% |
| Gross Margin | -865.42% | -59.29% | -246.91% | -306.55% |
| Cash Conversion Ratio | 0.51 | 0.68 | 1.06 | 1.03 |
| Growth | ||||
| Revenue 3-Year CAGR | -12.42% | 7.16% | 18.42% | -18.97% |
| Free Cash Flow Growth | -16.02% | 53.53% | -38.61% | -16.71% |
| Safety | ||||
| Net Debt / EBITDA | 0.41 | 1.31 | -0.00 | 0.02 |
| Interest Coverage | 0.00 | -100.27 | -143.17 | -34.83 |
| Efficiency | ||||
| Inventory Turnover | 3.79 | 0.95 | 1.40 | 2.28 |
| Cash Conversion Cycle | 227.07 | 857.46 | 1,185.82 | 403.88 |